Astrazeneca Ab

Acturum Life Science Ab

Alzecure Pharma Ab

Navidea Biopharmaceuticals, Inc.

Gunnar Nordvall

Daniel Sohn

Annika Kers

Tobias Rein

Can Slivo

Peter Robert Bernstein

Michael Balestra

Christian Erik Linde

Jonas Malmstrom

Colin Ray

Ylva Gravenfors

Per Jonas Malmborg

Dirk Reinhold Weigelt

Michael Quirk

David Wensbo

Katharina Högdin

Sverker Hanson

David Pyring

Pontus Forsell

Rolf Johansson

Gitte Terp

Tatjana Weigelt

Anh Johansson

Johan Andersson

Peter Strom

Catrin Jonasson

Stefan Von Berg

Sofia Karlstrom

Jörg Holenz

Alexander Minidis

Ulrika Yngve

Sofia Karlström

Jenny Viklund

Yevgeni Besidski

Kim Paulsen

Jonas Malmborg

Jonas Malmström

Helena Gyback

Istvan Macsari

Helena Gybäck

Johan Bylund

Maria E Ek

Karl S A Vallin

Karl SA Vallin

There is provided herein a compound of formula I, wherein R, R, n, X, Q, L, m, Rand p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.

Triazine derivatives for treating diseases relating to neurotrophins

There is provided a compound of formula (I), wherein R, R, R, Q, Q, Q, X, A and n are as defined herein, which compounds are useful in the treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.

4-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptors

There is provided herein a compound of formula (I) wherein R, R, n, X, Q, L, m, Rand p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like. 

Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.

NMDA antagonist prodrugs

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A&#x3b2;-related diseases. 

Triazole compounds and their use as gamma secretase modulators

There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R, R, R, Rand Rare as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CXCR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.

5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors

The invention provides compounds of formula (I) wherein R, R, L, L, G, G, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1. 

Bis-(sulfonylamino) derivatives for use in therapy

The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.

Heteroaryl substituted benzothiazoles

The present invention relates to compounds of formula (I), wherein The present invention further relates to new intermediates useful in the preparation thereof.

2-carboxamide-7-piperazinyl-benzofuran derivatives

2-carboxamide-7-piperazinyl-benzofuran derivatives 774

There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R, R, R, R, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.

Thioxanthine derivatives as myeloperoxidase inhibitors

The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: [Chemical formula should be inserted here. Please see paper copy] and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. 

There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R, R, R, Rand n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CXCR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain. 

5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy

Growing community of inventors

Sodertalje, Sweden

Gunnar Nordvall